The prevalence of hypertension is dramatically increasing worldwide, in part due to the aging population and rising rates of obesity. 1 While standard antihypertensive medication combined with lifestyle modification effectively controls blood pressure (BP) in many patients, up to 12% of patients do not obtain adequate control. 2 These patients, described as having resistant hypertension, have an elevated systolic BP (>140 mm Hg) despite prescription of at least 3, maximally tolerated doses of antihypertensive medication, including a diuretic. 1 Renal artery nerve denervation (RDN) using a monopolar radiofrequency catheter is a relatively new device-based technology, which disrupts the renal sympathetic nerves to ostensibly inhibit sympathetic activity. Renal sympathetic activity is typically elevated in patients with essential and resistant hypertension. 3, 4 This mechanism may explain why resistant hypertension is difficult to control. The renal nerves play a major role in controlling arterial pressure, via efferent nerves stimulating the release of renin, causing renal vasoconstriction, and sodium/water retention 5 and afferent nerves causing reflex increases in sympathetic outflow. 6 Consequently, inhibiting the renal sympathetic nerves has become an important therapeutic target (Figure 1) .
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Several studies have demonstrated a reduction in BP after RDN, which was associated with reductions in renal norepinephrine spillover 4 and muscle sympathetic nerve activity (MSNA) 7, 8 and resetting of the sympathetic baroreflex 9 in treated patients. However, the effects of RDN on the integrative response to common cardiovascular stimuli such as upright posture are unknown. During upright posture, the baroreflex mediates an increase in sympathetic activity to maintain arterial pressure. 10, 11 Prolonged maintenance of upright posture can be used to assess the responsiveness of the renin-angiotensin-aldosterone system (RAAS), which is slow to regulate BP in comparison to the rapid adjustments made via the baroreflex. Therefore, assessment of activity of the RAAS under unstressed conditions, such as supine resting, does not provide meaningful information about the integrity of the system. 12 We have previously demonstrated that the MSNA response to head-up-tilt (HUT) is augmented in hypertensive patients compared to matched normotensive controls, 13 and lowered following chronic renin inhibition. 14 Thus, this technique is sensitive and provides important information regarding integrative control of BP.
While several studies have reported favorable effects of the RDN procedure, others have found that the effects of RDN on sympathetic activity and BP are not consistent. [15] [16] [17] [18] Interestingly, none of these prior studies included a reliable assessment of blood flow (cardiac output, Qc) and resistance (total peripheral resistance, TPR), or response to upright posture, which is more reflective of free living conditions. To assist in the design of a prospective study of the efficacy of RDN and effect on integrative control of BP (Figure 1 ), we conducted a high-resolution physiological study in participants who had undergone RDN in the recent Symplicity HTN-3 study. 19 The aim of the study was to characterize BP control in the supine and upright posture post RDN. Overview of the integrative regulation of blood pressure. Blood pressure is a function of cardiac output (stroke volume and heart rate) as well as total peripheral resistance. In the case of enhanced renal sympathetic activity, the renin-angiotensin-aldosterone system is activated and renal blood flow is reduced, causing volume retention, sodium reabsorption, and ultimately elevating BP. (1) Denervation of the renal arteries is proposed to alter BP via a decrease in renal afferent and efferent nerve activity, (2) causing a reduction in both centrally mediated sympathetic outflow, thus reducing (3) muscle sympathetic nerve activity, (4) norepinephrine spillover and (5) vascular resistance and (6) in total peripheral resistance, thereby lowering blood pressure. In addition, reduced sympathetic activity to the heart (7) should reduce heart rate and thereby reduce cardiac output (8) and lower blood pressure. The decrease in renin, could lower blood pressure via reduction in aldosterone levels, blood volume and cardiac output, or alternatively a decrease in angiotensin II reducing peripheral vascular resistance. Abbreviations: BP, blood pressure; MSNA, muscle sympathetic nerve activity; CVLM, caudal ventrolateral medulla; NA, nucleus ambiguus; NE, norepinephrine; NTS, nucleus tractus solitraius; PAG, periaqueductal grey; PVN, paraventricular nucleus; RVLM, rostral ventrolateral medulla.
METHODS
Patients were eligible for inclusion if they had participated in the Symplicity HTN-3 study and received RDN (N = 12). This study included patients who had crossed over and received RDN after unblinding of the main trial (N = 3). 19 Exclusion criteria included evidence of peripheral neuropathy secondary to diabetes, because of the planned nerve microneurography. All participants provided written informed consent. The study received ethical clearance from the institutional review boards at UT Southwestern Medical Center, Texas Health Presbyterian Hospital Dallas, and the Baylor Scott and White Research Institute. This study adhered to the Declaration of Helsinki.
This study took place after assessment of the primary efficacy endpoint for the Symplicity HTN-3 study, 19 meaning patients were assessed in the chronic state, on average 27-months post RDN (range, 21-38 months). The investigators involved in data collection and analysis were blinded to the patient's treatment group. Medical history and current medication usage was documented in all patients. Two age-matched, control groups of normotensive (Norm), and mildly hypertensive (unmedicated; HTN) individuals were identified from previous studies in our laboratory investigating gender differences in BP regulation using identical methods, 14, [20] [21] [22] [23] and were compared to the RDN patients.
Measurements
Hemodynamics. The assessment of ambulatory BP was performed in a standardized manner, according to the Symplicity HTN-3 study protocol. 19 Hemodynamic measurements included heart rate (HR) determined from lead II of the ECG; brachial BP, measured by electrosphygmomanometry (Suntech Medical Instruments, Raleigh, NC) with a microphone over the brachial artery to detect Korotkoff sounds; and beat-by-beat BP measured by finger photoplethysmography (Nexfin, BMEYE, Amsterdam, The Netherlands). Qc was measured via the modified acetylene rebreathing technique. 24 Stroke volume was calculated from Qc divided by HR, and TPR was calculated as the quotient of mean BP [diastolic BP + (systolic BP − diastolic BP)/3] and Qc, multiplied by 80. Stroke volume, Qc, and TPR were indexed to body surface area to allow comparison between groups. Effective arterial elastance was calculated by end systolic pressure/stroke volume. End systolic pressure was assumed to be equal to systolic BP × 0.9, as previously reported. 25 Respiration was monitored via nasal cannula. Forearm blood flow in ml/100 ml tissue / min was recorded using venous occlusion plethysmography (Hokanson, WA) by standard techniques 26 at the same time as brachial BP was measured. Regional forearm vascular resistance was calculated as mean BP divided by forearm blood flow.
Sympathetic activity. Multiunit MSNA was assessed using the microneurographic technique, as previously described. 27, 28 Briefly, a recording electrode was inserted in the peroneal nerve at the level of the popliteal fossa, and a reference electrode was inserted subcutaneously 2-3 cm from the recording electrode. The nerve signals were amplified (70,000 to 160,000-fold), band-pass filtered (700 to 2,000 Hz), full-wave rectified, and integrated with a resistance-capacitance circuit (time constant 0.1 sec). Criteria for adequate MSNA recording included: (i) pulse synchrony; (ii) facilitation during the hypotensive phase of the Valsalva manoeuver, and suppression during the hypertensive overshoot after release; (iii) increases in response to breath holding; and (iv) insensitivity to a gentle skin touch or a loud shout. 27 
Study protocol
For a detail study protocol please refer to the Supplementary Material. In brief, patients were placed in the supine position, after 20 minutes, serial measurements of Qc, HR, and BP were performed until a stable measurement was achieved, generally 15-20 minutes. At least 10 minutes after a satisfactory nerve signal was acquired, baseline supine MSNA and beat-by-beat BP and HR were recorded for 6 minutes during spontaneous breathing. Following this, subjects were passively tilted to 30° for 5 minutes (equivalent to the seated posture) and then 60° for 20 minutes, or until presyncope. Throughout the entire experimental procedure continuous beat-by-beat BP, HR, respiratory waveforms, and MSNA were recorded. Blood samples were taken in the supine position and after 5 and 20 minutes of HUT 60° for assessment of plasma catecholamines; plasma renin activity, aldosterone, and vasopressin were measured supine and after 20 minutes of HUT 60°.
Total blood, plasma volume and red cell volume were then measured using the modified carbon monoxide rebreathing method in the seated position. 29 
Data analysis
Data analysis was performed as previously reported 10, 22 and detailed in the Supplementary Methods. The number of bursts per minute (burst frequency), the number of bursts per 100 heartbeats (burst incidence), and the burst area per minute (total activity) were used as quantitative indices.
Baseline supine MSNA indices and hemodynamics were averaged for 6 minutes during spontaneous breathing. Data for HUT 30° were collected and averaged from the second to the fifth minutes. Data for HUT 60° were averaged from the 2 nd to 5 th minute (5 minutes HUT 60°) and 16 th to the 19 th minutes (20 minutes HUT 60°). One patient developed presyncope in the RDN group, and the HUT test was terminated before the 20 th minute HUT 60° data collection. In the normotensive group, 2 subjects became presyncopal during tilting. The "last (stable) data carry forward" method for imputing missing HUT values was used. 30 
Statistical analysis
Values are expressed as means ± SD in table and text and mean ± SEM in figures where specified. Differences in patient characteristics and supine resting variables and blood volume were assessed using a 1-way analysis of variance. The least significant difference method was used as a post-hoc test for multiple comparisons. To assess the effect of RDN on the response to HUT, a 2-way repeated measures analysis of variance was used, with factors for group, posture, and interactions. The least significant difference method was used as a post-hoc test for multiple comparisons. A P value of <0.05 was considered statistically significant. Statistical analysis was performed using commercially available software (IBM SPSS and GraphPad Prism).
RESULTS

Patient characteristics
Twelve patients who had received RDN as part of the Symplicity HTN-3 study, were studied 27 ± 6 months posttreatment. Subjects received on average 11 ± 3 ablations, 2 subjects received only 4 and 8 ablations, respectively. The remaining subjects received 10 or more ablations. At the time of this study, the RDN group were medicated with an average of 4.8 (range, 3-7) antihypertensive medications. Despite the high use of antihypertensive therapy and treatment with RDN, the RDN group had significantly elevated ambulatory BP compared to age and sex matched, HTN, and Norm groups (Table 1) . A detailed summary of RDN antihypertensive medication usage and number of ablations is provided in the online Supplement (Table S1 ). The individual changes in office systolic and ambulatory BP as measured during the course of the Symplicity HTN-3 study are presented in Supplementary Figure S1 . As a group office and ambulatory systolic BP were reduced at 6 months and remained below baseline levels at approximately 27 month post enrolment in the HTN-3 study. Yet, there was large individual variability in the BP response, with several participants initially appearing to respond to RDN before BP rebounded.
Supine resting variables
In comparison to Norm and HTN subjects, the RDN group had markedly elevated supine brachial BP (Table 1 ). Figure 2 shows original tracings of integrated MSNA from a representative subject in each group in the supine and upright posture (HUT 60°). The higher BP in the RDN group was partially due to elevated sympathetic activity, as evidence by higher TPR, MSNA, and plasma norepinephrine compared to the Norm (Figure 3a , b, and d). MSNA and TPR were similar between the RDN and HTN groups, but plasma norepinephrine was significantly increased in the RDN group. Values are mean ± SD. **≤0.001 compared to Norm, *≤0.05 compared to Norm, † † ≤0.001 compared to HTN, † ≤0.05 compared to HTN. Abbreviations: ABPM, ambulatory blood pressure monitor; A.U., arbitrary unit; DBP, diastolic blood pressure; Ea, effective arterial elastance; HR, heart rate; HTN, hypertensive; HUT, head up tilt; MSNA, muscle sympathetic nerve activity; Qc, cardiac output; SBP, systolic blood pressure; SV, stroke volume; TPR, total peripheral resistance.
One African American female subject in the RDN group and one in the Norm group demonstrated very low baseline MSNA; they were considered outliers and were omitted from the statistical analysis (please see Supplementary Figure S2 ). Interestingly, despite 92% of RDN patients being treated with beta-blockers, supine HR was significantly elevated compared to Norm and HTN (Figure 3b ). In addition, effective arterial elastance, an index of afterload, was significantly higher in the RDN group, which would also contribute to the higher BP (Table 1) . Total blood, plasma, and red cell volume were similar among groups (Table 1) , arguing against a meaningful sustained reduction in plasma volume from RDN.
Response to upright tilt
The hemodynamic, neural, and humoral response to HUT is summarized in Figure 4 and Table 2 . The mean BP response to HUT was similar among groups, such that the RDN group demonstrated increased mean BP throughout the tilt compared to both other groups (Figure 4a ). Systolic BP was the primary contributor to the increase in mean pressure as diastolic BP was similar between the groups ( Table 2 ). The increase in BP was primarily due to elevated Qc in the RDN group, as the change from supine to upright posture in TPR and MSNA was similar between groups (Figure 4d and e) . However, we did observe a trend for increased MSNA burst frequency in the RDN group compared to the Norm group throughout tilt (P = 0.13). Although the response of the components of Qc (HR and SV) to HUT were similar, the mean HR and SV trended to be higher in the RDN group (main effect group P = 0.23 and P = 0.24, respectively); yet, this did not achieve conventionally accepted levels of statistical significance. The RDN group demonstrated significantly higher plasma norepinephrine levels throughout tilt ( Table 2) .
We observed a wide range of plasma renin levels in the RDN group in the supine, (median interquartile range, 0.9 [0.1-3.4] ng/ml/hg) and upright posture (median interquartile range, 2.3 [0.2-4.2] ng/ml/hg), which is consistent with hypertensive subjects. 31 Yet, despite this, the response of aldosterone levels were higher in the RDN subjects compared to other groups (Table 2) .
DISCUSSION
We report for the first time a detailed integrative assessment of BP regulation in the supine and upright posture in patients with resistant hypertension who have received RDN. The main findings are as follows; despite treatment with RDN and optimal antihypertensive therapy, this group of patients with resistant hypertension demonstrated elevated BP in the supine and upright posture compared to mildly hypertensive and normotensive age and sex matched controls. Using integrative and high-resolution "physiomics", we identified several possible mechanisms contributing to the elevated BP in this group of patients who have received RDN, including; elevated sympathetic activity, increased systemic arterial stiffness, and augmented RAAS.
Since the publication of the main findings from the Simplicity HTN-3 study, there has been much discussion about the strengths and weaknesses of the trial design, and the technique itself. [32] [33] [34] Perhaps one of the most pertinent issues is the unavailability of a real time assessment of procedural success. Thus, only a change in BP was used to determine the success of the procedure in clinical trials, rather than a measured change in sympathetic activity in the kidney. RDN has been shown to reduce renal norepinephrine spillover, a surrogate marker for renal sympathetic nerve activity, and MSNA. 4, 7, 8, 35 We found in this group of RDN subjects, that sympathetic activity was elevated in the supine posture compared to normotensive controls, which may partially explain why BP levels remain poorly controlled.
Another recommendation is that detailed physiological profiling of patients before and after RDN could ensure that the most suitable patients are treated. 32, 36, 37 While several studies have assessed the effect of RDN on sympathetic activity (as discussed above), to our knowledge, no studies have included a reliable and accurate measurement of the key components of BP: namely Qc (flow) and TPR (resistance). TPR was increased in the RDN subjects compared to the normotensive controls, which is consistent with the observation of elevated MSNA in the supine posture. In addition, Qc was also increased in the RDN group. Contributing to the increase in Qc, TPR and sympathoexcitatory state, were higher concentrations of aldosterone and plasma norepinephrine. Thus, BP in the supine posture in RDN subjects was increased due to several factors including neural and hormonal factors.
Integrative BP control during upright tilt
The integrative BP response to upright posture has not been characterized using high resolution, beat-by-beat physiological techniques in patients with resistant hypertension. The response to upright posture provides a window into Comparison of supine resting blood pressure (a), heart rate (b), MSNA (c) and plasma norepinephrine (d) in RDN subjects, unmedicated mild HTN and Norm subjects. Mean BP, heart rate and plasma norepinephrine levels were significantly higher in the RDN subjects than both other groups, while MSNA was significantly higher in the RDN vs. Norm group only. *P ≤ 0.05. Abbreviations: HTN, hypertensive; MSNA, muscle sympathetic nerve activity; Norm, normotensive; RDN, renal denervation.
individual dynamic BP regulation, which is possibly more reflective of daily life than studies of supine rest. In the present study, the hemodynamic and MSNA response to upright tilt (change from supine to upright) was similar among groups. However, we observed a trend for significantly higher MSNA burst frequency in the RDN group compared with the Norm group when upright. Moreover, mean BP was also much higher in the RDN group throughout tilt. The increase in BP was due to a combination of factors. Indeed, plasma norepinephrine levels were elevated providing further evidence that sympathetic activity was higher in the RDN group. This finding may be due to a change in norepinephrine release, reuptake, or clearance or due to increases in sympathetic activity in other vascular beds.
Furthermore, the elevated BP may reflect arterial remodeling, which has occurred because of hypertension 38 or disturbances in local vasoactive factors which regulate the diameter of blood vessels, e.g., nitric oxide. Indeed, systolic BP and effective arterial elastance were increased in the RDN subjects. This finding suggests that in patients with resistant hypertension who have received RDN, systemic arterial antimodeling has not occurred and thus systolic BP remains elevated as a consequence. A decrease in arterial compliance may also have influenced the sensitivity of the baroreflex. Increased arterial stiffness reduces the distensibility of the baroreceptors and thus alters the effectiveness of the mechanosensory transduction in response to vascular wall stretch. 39 Decreased compliance in the carotid and aortic baroreceptors may explain why the BP operating point is higher in the RDN group than HTN and Norm groups.
Finally, the high baseline levels of aldosterone and Qc also provide some insight to plausible mechanism for the persistently elevated BP. Elevated aldosterone levels suggests that angiotensin II levels were increased, as patients Figure 4 . Comparison of the hemodynamic and neural response to head up tilt in RDN subjects, with HTN and Norm control subjects. Mean blood pressure (a) was higher in the RDN subjects; however, the response to HUT was similar between groups. The heart rate (b) and (c) total peripheral resistance was similar between groups, while Qc remained higher in the RDN group (d). The neural response, as assessed by the change in burst frequency (e) and change from baseline in total activity (f) was also similar among the groups. Total activity was analyzable in n = 9 subjects in the RDN group and n = 11 subjects in the NORM group. *P ≤0.05 compared to Norm under the same condition, † P ≤0.05 compared to HTN under the same condition. Abbreviations: HR, heart rate; HUT, head up tilt; MAP, mean arterial pressure; MSNA, muscle sympathetic nerve activity; Norm, normotensive; Qc, cardiac output; RDN, renal denervation; HTN, hypertensive; TPR, total peripheral resistance.
with primary aldosterone syndrome were excluded from the main trial. 19 We observed a wide range of resting plasma renin levels, which is consistent with population based studies in hypertensive subjects. 31 Low renin activity, does not preclude the effects of tissue angiotensin II (for example, vascular endothelium, kidneys, brain, and the adrenal glands). 40 Elevated angiotensin II may contribute to elevated BP in several ways (i) via direct effects on the vasculature, e.g., increasing TPR; (ii) increasing sodium and fluid retention via the actions of aldosterone and increasing Qc; or (iii) via central effects. Combined these factors contributed to the higher BP observed in the RDN subjects.
The main limitation of this study is the cross-sectional nature of this study. A much more robust experimental design would have included assessment of our measures of integrated BP control both prior to and following RDN. Therefore, our results are unable to demonstrate causality and the findings are hypothesis generating. Our results suggest that future studies should incorporate a more integrative assessment of BP, including an accurate and reliable measure of Qc as used in this study. 24 Other factors, which may alter outcomes (e.g., medication changes, lifestyle changes, disease progression, comorbidities, etc) were not controlled in this long-term study. Nor was medication compliance assessed comprehensively, e.g., via drug testing. 41 Patients were studied approximately 2 years post RDN when study monitoring for the Symplicity HTN-3 trial was far less intensive. The variability between participants post assessment may potentially confound our results. In a recent study, it was suggested that that reinnervation of renal afferent and One subject in the Norm group was excluded from the Epinephrine analysis, as they were outliers. Values are means ± SD. HUT indicates head up tilt. *≤0.05 compared to Norm, † ≤0.05 compared to HTN. Analysis for catecholamines included n = 11 for RDN and HTN subjects. Missing data was due to insufficient sample for reliable analysis. Abbreviations: HTN, hypertensive; HUT, head up tilt; RDN, renal denervation. efferent nerves was evident at 11 months post denervation. 42 The authors reported that renal sympathetic nerve activity had returned, as the response to electrical stimulation was considered normal and the distribution of afferent and efferent nerves within the kidney was also normal, all inferring that the effects of RDN is not permanent. We are unable to rule out that the participants study may also have experienced some degree of reinnervation. Indeed, there was wide individual variability in the BP response. An additional limitation is the small sample size; however, the number is similar to other studies, which have assessed the effects of RDN on sympathetic nerve activity. 15, 17, 35 Indeed, the observed MSNA levels are similar to those reported by Hering et al., at 1-year postrenal denervation. 35 In the present study, we chose to study patients on antihypertensive medication, as (i) it is impractical to withhold medication in this population for extended periods and (ii) it provides a representative assessment of the individual's daily hemodynamic state as patient were being studied in the chronic state post RDN. It must be noted that some antihypertensive medication prescribed to lower BP may contribute to inadequate BP control via activating the sympathetic baroreflex. 13, 43 Medications that lower BP through peripheral vasodilatory effects can cause a compensatory baroreflex mediated increase in MSNA. 13 Indeed, blockade of calcium channels via amlodipine reduced BP but caused an increase in MSNA and HR. 44 In contrast, angiotensin II blockade through valsartan decreases BP without augmenting the sympathetic nervous system, thus suggesting a shift in the baroreflex operating point. 44 Moderate doses of sympatholytic drugs such as clonidine 45 reduce BP and sympathetic activity. Presently, there are no studies examining the indirect and cumulative effects of different antihypertensive drug regimens on RDN. In light of this, the interaction between antihypertensive drugs and RDN may have influenced the results of our study.
In conclusion, through the use of high-resolution "physiomics" testing, we were able to characterize BP regulation in subjects who had previously undergone RDN. The findings from our study demonstrate that RDN subjects who participated in the Symplicity HTN-3 study have elevated sympathetic and aldosterone levels at approximately 2 years post treatment associated with elevations in both TPR and Qc. These findings may be the consequence of incomplete ablation of sympathetic renal nerves as part of the Symplicity HTN-3 study or be related to other factors including medication usage and/or upregulation of compensatory reflex mechanisms. Alternatively, in some patients with resistant hypertension, current pharmacological and technological treatments are ineffective for normalizing BP. Ultimately, our study highlights that all device therapies, including RDN, need to consider patient factors, procedural factors, and situational factors that may modify the response to treatment, both in the short term and more chronically. Substudies including high-resolution physiological assessments investigating the mechanisms underlying the response to treatment should be strongly considered as part of all clinical trials proposing new device therapies for hypertension.
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